Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel partnership with US healthcare firm Organon (NYSE: OGN) to market women’s health products in China. SPH will take full responsibility for the domestic marketing of Organon’s gynecology and fertility regulation offerings, including Livial (tibolone), Mercilon (ethinylestradiol, desogestrel), and Nexplanon (etonogestrel). Financial terms of the agreement were not disclosed.

Partnership Scope
Under the agreement, SPH will leverage its market presence to distribute and promote Organon’s women’s health products across China. This strategic move aims to enhance the accessibility and availability of these therapies for patients nationwide.

Product Portfolio
Organon’s products, including Livial for menopausal symptoms, Mercilon for contraception, and Nexplanon for long-acting reversible contraception, are well-established in the women’s health sector. SPH’s marketing efforts will focus on maximizing these products’ potential in the Chinese healthcare market.-Fineline Info & Tech